

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ANDERSON DAVID L</u> (Last) (First) (Middle) <u>755 PAGE MILL ROAD, SUITE A-200</u> (Street) <u>PALO ALTO CA 943041005</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/14/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
--	---	--	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(2)	Common Stock	70,548	0.0000 ⁽³⁾	I	By Ltd Partnership ⁽⁴⁾
Series A Preferred Stock	(1)	(2)	Common Stock	8,019	0.0000 ⁽³⁾	I	By Ltd Partnership (SHAI) ⁽⁵⁾
Series A Preferred Stock	(1)	(2)	Common Stock	20,304	0.0000 ⁽³⁾	I	By Ltd Partnership (SHQP) ⁽⁶⁾
Series A Preferred Stock	(1)	(2)	Common Stock	791,586	0.0000 ⁽³⁾	I	By Ltd Partnership (SHV) ⁽⁷⁾
Series A Preferred Stock	(1)	(2)	Common Stock	53,145	0.0000 ⁽³⁾	I	By Trust ⁽⁸⁾
Series B Preferred Stock	(1)	(2)	Common Stock	77,322	0.0000 ⁽³⁾	I	By Ltd Partnership ⁽⁴⁾
Series B Preferred Stock	(1)	(2)	Common Stock	5,775	0.0000 ⁽³⁾	I	By Ltd Partnership (SHAI) ⁽⁵⁾
Series B Preferred Stock	(1)	(2)	Common Stock	14,619	0.0000 ⁽³⁾	I	By Ltd Partnership (SHQP) ⁽⁶⁾
Series B Preferred Stock	(1)	(2)	Common Stock	569,940	0.0000 ⁽³⁾	I	By Ltd Partnership (SHV) ⁽⁷⁾
Series B Preferred Stock	(1)	(2)	Common Stock	9,318	0.0000 ⁽³⁾	I	By Trust ⁽⁸⁾
Series BB Preferred Stock	(1)	(2)	Common Stock	15,761	0.0000 ⁽⁹⁾	I	By Ltd Partnership ⁽⁴⁾
Series BB Preferred Stock	(1)	(2)	Common Stock	1,228	0.0000 ⁽⁹⁾	I	By Ltd Partnership (SHAI) ⁽⁵⁾
Series BB Preferred Stock	(1)	(2)	Common Stock	3,109	0.0000 ⁽⁹⁾	I	By Ltd Partnership (SHQP) ⁽⁶⁾
Series BB Preferred Stock	(1)	(2)	Common Stock	121,780	0.0000 ⁽⁹⁾	I	By Ltd Partnership (SHV) ⁽⁷⁾
Series BB Preferred Stock	(1)	(2)	Common Stock	1,991	0.0000 ⁽⁹⁾	I	By Trust ⁽⁸⁾
Series C Preferred Stock	(1)	(2)	Common Stock	51,503	0.0000 ⁽⁹⁾	I	By Ltd Partnership ⁽⁴⁾
Series C Preferred Stock	(1)	(2)	Common Stock	7,400	0.0000 ⁽⁹⁾	I	By Ltd Partnership (SHAI) ⁽⁵⁾

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series C Preferred Stock	(1)	(2)	Common Stock	18,736	0.0000 ⁽⁹⁾	I	By Ltd Partnership (SHQP) ⁽⁶⁾
Series C Preferred Stock	(1)	(2)	Common Stock	732,882	0.0000 ⁽⁹⁾	I	By Ltd Partnership (SHV) ⁽⁷⁾
Series C Preferred Stock	(1)	(2)	Common Stock	55,527	0.0000 ⁽⁹⁾	I	By Trust ⁽⁸⁾

Explanation of Responses:

1. Immediately.
2. Not applicable.
3. Each preferred share is convertible without consideration into three (3) shares of common stock.
4. Shares held by a limited partnership of which the reporting person is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.
5. Shares held by Sutter Hill Entrepreneurs Fund (AI), L.P. The reporting person is a Managing Director of the General Partner of Sutter Hill Entrepreneurs Fund (AI), L.P. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.
6. Shares held by Sutter Hill Entrepreneurs Fund (QP), L.P. The reporting person is a Managing Director of the General Partner of Sutter Hill Entrepreneurs Fund (QP), L.P. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.
7. Shares held by Sutter Hill Ventures, A California Limited Partnership. The reporting person is a Managing Director of the General Partner of Sutter Hill Ventures, A California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.
8. Shares held by a trust of which the reporting person is the trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
9. Each preferred share is convertible without consideration into one (1) share of common stock.

Remarks:

By: Robert Yin, by power of attorney 04/14/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes David E. Sweet, Robert Yin, Patricia Tom, G. Leonard Baker, Jr., Tench Coxé, James C. Gaither, Gregory P. Sands, James N. White, or William H. Younger, Jr. to execute for and on behalf of the undersigned Forms 3, 4, and 5, and any Amendments thereto for Corcept Therapeutics, Incorporated ("the Company"), and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such a capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

In witness whereof, the undersigned has caused this Power of Attorney to be executed as of this 13th day of April, 2004.

/s/ David L. Anderson